ERBB2 and gastric adenocarcinoma: It consists of a humanized, monoclonal, anti-HER2 antibody bound to a topoisomerase I inhibitor via a peptide-based linker demonstrated an excellent clinical efficacy of trastuzumab deruxtecan (T-DXd) in HER2-positive advanced gastric adenocarcinoma [10,11].